Does tirzepatide make you tired? For a minority of people, yes. Fatigue is a listed adverse reaction in the prescribing information for branded tirzepatide, reported by 5% of participants at 5 mg, 6% at 10 mg and 7% at 15 mg, against 3% on placebo. That makes it real and dose-related, and far less common than the gastrointestinal reactions that dominate the profile. It is also rarely the molecule acting directly on your energy system. Far more often it is a downstream consequence of eating much less, losing fluid, or sleeping differently.
What the trials and the labelling actually report
Fatigue sits in the adverse-reaction table built from the 72-week obesity trials:
| Group | Fatigue reported |
|---|---|
| Placebo | 3% |
| Tirzepatide 5 mg | 5% |
| Tirzepatide 10 mg | 6% |
| Tirzepatide 15 mg | 7% |
For scale, nausea in the same table ran 25–29% and diarrhoea 19–23%. Fatigue is a second-tier reaction, not a headline one.
Those trials are SURMOUNT-1, which randomised 2,539 adults with obesity or overweight and no diabetes (Jastreboff et al., NEJM 2022), and SURMOUNT-2 in adults with type 2 diabetes (Garvey et al., Lancet 2023). Neither found fatigue to be a leading reason people stopped: discontinuation for adverse events in SURMOUNT-1 ran 4.3% to 7.1% across the tirzepatide arms against 2.6% on placebo, and gastrointestinal events accounted for most of it.
What the trials do not do is explain the tiredness. For that you have to look at what else changes when the medication starts working. Tirzepatide side effects covers the wider profile; this page is about the energy question specifically.
Does tirzepatide make you tired, or is it the weight loss?
Mostly the second, and the distinction matters because each mechanism has a different answer behind it.
Eating substantially less, quickly
The medication works by reducing appetite, so intake falls — often sharply, and often before anyone has adjusted what they eat to fit the smaller appetite. In a study measuring appetite and food intake directly, tirzepatide 15 mg significantly reduced appetite scores and energy intake compared with placebo over 28 weeks (Heise et al., Diabetes Care 2023). A sudden energy deficit is felt as flatness, most noticeably in the first weeks and after each dose step.
Fluid loss from gastrointestinal reactions
Nausea, vomiting and diarrhoea move fluid out of the body. The labelling for branded tirzepatide carries a warning about acute kidney injury in patients who became volume-depleted through exactly those reactions, and advises monitoring kidney function during initiation and dose escalation. Long before dehydration becomes a kidney problem it shows up as tiredness, light-headedness on standing and a headache that will not clear.
Low blood sugar in combination with other diabetes medication
On its own, tirzepatide seldom causes hypoglycaemia. In combination it is a different picture. In the type 2 diabetes trial behind the label, blood glucose below 54 mg/dL was reported in 4.2% of tirzepatide-treated participants against 1.3% on placebo — and among those also taking a sulfonylurea it was 10.3%, against 2.1% of those not taking one. The labelling notes that a dose reduction of insulin or the secretagogue may be necessary. That adjustment belongs to the prescriber, not to the person taking it.
Sleep that changes shape
Nausea or reflux late in the evening fragments sleep, and fragmented sleep is felt the next afternoon rather than the next morning. Weight change also moves sleep in the opposite direction: in SURMOUNT-OSA, tirzepatide reduced the apnoea–hypopnoea index substantially in adults with obesity and moderate-to-severe obstructive sleep apnoea (Malhotra et al., NEJM 2024). Untreated sleep apnoea is one of the commonest causes of daytime tiredness in this population, which is why tirzepatide for sleep apnea is a live clinical question.
Nutrient intake falling with total intake
Weight comes off fast on this class. In the SURMOUNT-1 body-composition substudy, weight fell 21.3%, fat mass 33.9% and lean mass 10.9% by week 72; roughly 75% of what was lost was fat and 25% lean, the same proportion as in the placebo group (Look et al., Diabetes Obes Metab 2025). Eating much less also means taking in less of everything — protein, iron, B12 — and shortfalls in those present as fatigue. Whether that is what is happening is a question bloodwork answers. It is not something to guess at, and it is not a reason to start adding products of your own choosing on top of a prescription.
The same considerations run across the GLP-1 class
None of this is unique to tirzepatide. Semaglutide's labelling reports fatigue in 11% of treated adults against 5% on placebo, and the mechanisms behind it are the same ones — reduced intake, fluid losses during titration, altered sleep, and hypoglycaemia where other glucose-lowering medication is in play. If you are weighing the two molecules, the tiredness question does not separate them.
What tends to settle, and what does not
The gastrointestinal reactions that drive much of this are concentrated in the dose-escalation period. A pooled analysis across the SURMOUNT-1 to -4 trials found them mostly mild to moderate, occurring primarily during escalation, diminishing over time and rarely leading to discontinuation (Rubino et al., Diabetes Obes Metab 2025). Tiredness that tracks nausea usually follows the same curve.
Fatigue's own time course is not reported separately in the trial publications, so that pattern is inference from the mechanism rather than a measured finding, and it is worth saying so. What is measured is that stepping up dose raises the reported rate, which is one reason titration schedules are slow by design — see tirzepatide dosage and the titration ladder for how that progression is normally structured. Holding at a dose for longer is a recognised option, and it is a decision for the prescriber who wrote the prescription.
What warrants a call rather than waiting it out
- Tiredness with dizziness on standing, a dry mouth, or noticeably reduced urination — the dehydration picture.
- Shakiness, sweating, confusion or a racing heart, particularly alongside insulin or a sulfonylurea.
- Severe, persistent abdominal pain, especially radiating to the back, with or without vomiting.
- Fatigue that deepens rather than plateaus, or that begins well after a dose has been stable.
- Breathlessness, unusual pallor, or a heart rate that feels wrong at rest.
Reporting these early is the entire point of having a clinician attached to the prescription. A provider can look at the dose, the titration pace, the other medications on the list and the bloodwork together.
Where the compounded formulation fits
Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. The percentages quoted above come from trials of the branded product, and they remain the best evidence available for how the molecule behaves in people. A licensed provider may still prescribe a compounded formulation where they judge it appropriate — that decision is between you and your doctor. Compounded tirzepatide sets out what the distinction means in practice.
A licensed provider in Promise's prescriber network reviews every request and prescribes only where it is appropriate; not everyone qualifies. Tiredness that starts after treatment begins is precisely the kind of thing that relationship exists to handle, and keeping it in front of a clinician is how the rest of the plan stays intact.